<p class="title">Scientists have found an injectable gel that may help regrow cardiac muscles after heart attack.</p>.<p class="bodytext">The gel slowly releases short gene sequences known as microRNAs into the heart muscle, according to researchers at the University of Pennsylvania in the US.</p>.<p class="bodytext">After a heart attack, there is a dramatic loss of these heart muscle cells and those that survive cannot effectively replicate.</p>.<p class="bodytext">With fewer of these contractile cells, known as cardiomyocytes, the heart pumps less blood with each beat, leading to the increased mortality associated with heart disease.</p>.<p class="bodytext">For the study, published in the journal Nature Biomedical Engineering, the researchers used mouse models to demonstrate a new approach to restart replication in existing cardiomyocytes.</p>.<p class="bodytext">Though the reasons cardiomyocytes do not regenerate are not fully understood, the researchers used microRNAs that target signalling pathways related to cell proliferation.</p>.<p class="bodytext">They were able to inhibit some of the inherent "stop" signals that keep cardiomyocytes from replicating. This resulted in cardiomyocytes reactivating their proliferative potential.</p>.<p class="bodytext">With more heart cells dividing and reproducing, mice treated with this gel after heart attack showed improved recovery in key clinically relevant categories.</p>.<p class="bodytext">"Biologic drugs turn over very fast. The microRNAs that we used last less than eight hours in the bloodstream, so having a high local concentration has strong advantages," said Edward Morrisey, from the University of Pennsylvania.</p>.<p class="bodytext">Their short lifespan means that if patients were treated systemically, they would need to be injected frequently with large doses to ensure that a sufficient amount of microRNAs reaches their target in the heart.</p>.<p class="bodytext">Since these microRNAs are designed to promote cell proliferation, there would be a risk of tumour-producing, off-target effects.</p>.<p class="bodytext">"The most important traits of this gel are that it is shear-thinning and self-healing. Shear-thinning means it has bonds that can be broken under mechanical stress, making it more fluid and allowing it to flow through a syringe or catheter," said Jason Burdick, from the University of Pennsylvania.</p>.<p class="bodytext">"Self-healing means that when that stress is removed, the gel's bonds re-form, allowing it to stay in place within the heart muscle," Burdick said. </p>
<p class="title">Scientists have found an injectable gel that may help regrow cardiac muscles after heart attack.</p>.<p class="bodytext">The gel slowly releases short gene sequences known as microRNAs into the heart muscle, according to researchers at the University of Pennsylvania in the US.</p>.<p class="bodytext">After a heart attack, there is a dramatic loss of these heart muscle cells and those that survive cannot effectively replicate.</p>.<p class="bodytext">With fewer of these contractile cells, known as cardiomyocytes, the heart pumps less blood with each beat, leading to the increased mortality associated with heart disease.</p>.<p class="bodytext">For the study, published in the journal Nature Biomedical Engineering, the researchers used mouse models to demonstrate a new approach to restart replication in existing cardiomyocytes.</p>.<p class="bodytext">Though the reasons cardiomyocytes do not regenerate are not fully understood, the researchers used microRNAs that target signalling pathways related to cell proliferation.</p>.<p class="bodytext">They were able to inhibit some of the inherent "stop" signals that keep cardiomyocytes from replicating. This resulted in cardiomyocytes reactivating their proliferative potential.</p>.<p class="bodytext">With more heart cells dividing and reproducing, mice treated with this gel after heart attack showed improved recovery in key clinically relevant categories.</p>.<p class="bodytext">"Biologic drugs turn over very fast. The microRNAs that we used last less than eight hours in the bloodstream, so having a high local concentration has strong advantages," said Edward Morrisey, from the University of Pennsylvania.</p>.<p class="bodytext">Their short lifespan means that if patients were treated systemically, they would need to be injected frequently with large doses to ensure that a sufficient amount of microRNAs reaches their target in the heart.</p>.<p class="bodytext">Since these microRNAs are designed to promote cell proliferation, there would be a risk of tumour-producing, off-target effects.</p>.<p class="bodytext">"The most important traits of this gel are that it is shear-thinning and self-healing. Shear-thinning means it has bonds that can be broken under mechanical stress, making it more fluid and allowing it to flow through a syringe or catheter," said Jason Burdick, from the University of Pennsylvania.</p>.<p class="bodytext">"Self-healing means that when that stress is removed, the gel's bonds re-form, allowing it to stay in place within the heart muscle," Burdick said. </p>